Fibroscan 01
8
Fibro Scan ® PROVEN SOURCES
Transcript of Fibroscan 01
FibroScan®
Proven sources
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
WHO estimates that 3% of the world’s population are infected with HCV and are at risk of developing liver cirrhosis and/or liver cancer. And that of the 2 billion people who have been infected with the hepatitis B virus (HBV), more than 350 million have chronic (lifelong) infections.
From all around the world, more and more experts bring their testimonies on the FibroScan® and its dedicated probe efficiency on different diseases such as:
L i v e r d i S e a S e
“Transient elastography can be performed for the staging of liver fibrosis independent from the underlyng liver disease”M. Friedrich-rust et Al., eAsl 2007.
L i v e r c o m p L i c a T i o n S
“The FibroScan® is a potentially useful adjunct to assess risk of liver decompensation and complications among liver cancer patients undergoing liver resection”l. lAi et Al., APAsl 2007.
( L T x ) T r a n S p L a n T a T i o n
“el FibroScan® es un método simple para cuantificar el grado de FH en pacientes trasplantados hepáticos”J.c. MArín GAbriel et Al., Aeeh 2007.
c o - i n F e c T i o n d i S e a S e S ( H i v )
“our study confirms the relevance of FibroScan® to evaluate fibrosis in Hiv/HBv co-infected patients”P. MiAilhes et Al., crOi 2007.
Liver diseasesa worldwide concern
Viral Hepatitis, Nash, Alcoholism, Haemocromatosis, Diabetes, Mucovisidose… are all related to fibrosis
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
More than 250 FibroScan® are used all around the world.
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
CHrONiC HePaTiTis C ZiOl et al.
Non invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis C.Hepatology 2005 | vol. 41, n° 1, 2005
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
} MulticentricFrenchstudywith251patientswithchronichepatitisC.CorrelationFibroScan®vsbiopsy.
}GoodcorrelationbetweenFibroScan®andBiopsy.Distinguishclearlysignificant(F2)fibrosisfromotherstages.
}Establishstrongperformanceoncirrhosisdiagnosis.(F4)
}OptimalcutoffforFibroScan®F2:8.7kPa(sensi.:0.55;speci.:0.84)andF4:14.5kPa(sensi.:0.84;speci.:0.94).
}ThisstudyalsoestablishesthatinCHC,thecorrelationbetweenliverstiffnessandfibrosisstageisnotaffectedbysteatosisoractivitygrade.
}Fibrosis quantification is the key indicator in chronic liver disease evaluation.
}Accurate for cirrhosis diagnosis.
}Show limits of the biopsy due to the sample size and then a potential underestimation of the FibroScan® results.
}Takadaetal.Gastroenterology2006.12:7768-7773.
}AbstractDeLédinghenetal.AASLD2006x2.
cAsterA et al.
Prospective comparison of Transient Elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C.Gastroenterology 2005 | 128:343-350.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}MonocentricFrenchstudywith183patientswithchronichepatitisC.
}Comparediagnosisaccuracybetween,FibroTest,APRIandFibroScan®ascombinedvs.biopsy.
}OptimalcutoffforFibroScan®F2:7.1kPa(sensi.:0.67;speci.:0.89)andF4:12.5kPa(sensi:0.87;speci.:0.91).
}ThebestresultobtainedforF2wasacombinationofFibroScan®andFibroTest.ButforF4detection,theFibroScan®stand-aloneachievesthebestperformance.
}Accurate for cirrhosis diagnosis.
}PosterEASL2006complete1ststudywithlokindexandoralpresentationtoDDW2006FIBROSCAN®bestincirrhosis.
}AbstractSerjoetal.AASLD2006.
BiLiarY diseases cOrPechOt et al.
Assessment of Biliary Fibrosis by Transient Elastography in Patients with PBC and PSC.Hepatology 2006 | 43:1118-1124.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}MulticentricFrenchstudywith95patientswithbiliarycirrhosisorprimarysclerosingcholangitis.
}AssessthediagnosisperformanceofFibroScan®todeterminethefibrosisstageinchroniccholestaticdiseaseswithmetavirandLudwigscore.
}ExcellentcorrelationbetweenFibroScan®andBiopsy.ResultsareevenbetterthanthosereportedonHCV.
}FibroScan®ismoreaccuratethananyothernon-invasivetests.PBCvalidatedand1°accuratereportonPSC.
}OptimalcutoffforFibroScan®F2:7.3kPa(sensi.:0.82;speci.:0.79)andF4:17.3kPa(sensi.:0.87;speci.:0.95).
}Reliable and simple tool to assess liver fibrosis in different stages with chronic cholestatic diseases.
}Accurate for assessing fibrosis stage in different chronic liver diseases.
}AbstractGomez-DomingezAASLD2006.
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
HCv-Hiv CO-iNFeCTiON de ledinGhen et al.
Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus–Co-infected PatientsJAIDS 2005 | 43:1118-1124.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}Multicentric French study with 72 HIV-HCV co-infectedpatients. Assessing liver fibrosis with FibroScan® andcomparetoothernoninvasivemethods.
}Thestudyestablishes that liver stiffness is significantlycorrelatedtoLiverfibrosisalsoinco-infectedpatients.
}ComparetoAPRIindex,ASTALT,FIB-4andplateletcount.
}ThestudydemonstratesFibroScan®hasthebestsensibilityoncirrhosisdiagnosisvs.othertests.
}Optimal cut off for FibroScan®: 11.8 kPa for F4 (sensi.:1.00;speci.:0.93).
}FibroScan®isnotunpairedbytreatment,HIVordenutritionvs.othermarkers.
}FibroScan® can be the first line of therapeutic evaluation in HIV-HCV co-infected patients.
}Direct/applicable where other markers fail.
}Precise, reliable and accurate for cirrhosis diagnosis.
}FS : no restrictions except ascite.
}Kelletieretal.JHepatol2006;44:5126-5131.
}Masakietal.HepatolReasearch2006;36:135-139.
bArreirO et al.
Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3JAIDS 2005 | 43:1118-1124.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}MonocenticSpanishstudywith283HIV-HCVco-infectedpatients.
}1sttimethatFibroScan®isusedasareferencetooloffibrosisquantification.
}Liverfibrosisprogressfasterinco-infectedpatient.Thestudylooksfortheaccelerationfactor.
}HighlightusefulnessofFibroScan®tobringnewinsightsintonaturalhistoryofHCVco-infection.
}Gen3,olderageandhighalamineaminotransferaselevelareindependentpredictorsforanadvancedliverfibrosisinHIV-HCVpatient.
}Unique. FibroScan® used as a standard tool.
}Precise, reliable and accurate for fibrosis evaluation in chronic liver diseases.
}AbstractDeLédinghenetal.AASLD2006.
Liver TraNsPLaNTaTiON cArriOn et al.
Transient Elastography for diagnosis of advance fibrosis and portal hypertension in patients with Hepatitis C recurrence after liver transplantationLiver transplantation 2006 | 43:1118-1124.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}MonocentricSpanishstudywith124HCVtransplantedpatients.
}ThisstudyintendstoverifythatFibroScan®canavoidbiopsyafterLTxonHCVpatients.
}ThepurposeistoestablishacorrelationbetweenFibroScan®andHVPG.
}Costevaluation.
}Totally non-invasive.}Repeatable (allow a
close monitoring).}Precise, reliable and accurate
for cirrhosis diagnosis.}Cost efficient.
}AbstractRigamontietal.AASLD2006.
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
CirrHOsis aNd iTs COMPLiCaTiONs FOucher et al.
Diagnosis of cirrhosis by Transient Elastography (FibroScan®): a prospective study.GUT 2006 | 55:403–408.
s u m m a r y K e y s p o i n t s D o c a s s o c i at e D
}MonocentricFrenchstudywith711patientswithmultiplechronicliveretiologies.
}PurposeofthestudyistoassesstheaccuracyofFibroScan®incirrhosisdetectionwithchronicliverdiseases.
}Resultsestablishthatstiffnesswassignificantlycorrelatedwithfibrosis.Cirrhoticpatientsweredetectedwithapositivepredictivevalueandanegativepredictivevalueof90%.
}ThisstudyestablishesacorrelationbetweenliverstiffnessandFibroScan®.
}Accurate for all chronic liver diseases whatever the etiology.
}Accurate for cirrhosis diagnosis.
}Precise as a predictive factor of complications.
}Ganne-CarrieHepatol2006,44:1511-1517.
}Kozemietal.JHepatol2006,45(2):230-235.
}AbstractLemoineetal.AASLD2006.
®
e c h o s e n s | F i b r o s c a n ® P r o v e n s o u r c e s
FibroScan®
THe firsT And only ToTAlly non-inVAsiVe HepATiC fiBrosis diAgnosTiC And moniToring deViCe
FS 502
and its dedicated probe
*fo
r f
ur
THer
in
for
mA
Tio
n -
Co
mm
un
iCA
Tio
n@
eCH
ose
ns.
Com
– w
ww
.eCH
ose
ns.
Com
What is the unique totally non-invasive device able
to detect liver fibrosis whatever the etiology?
Have you ever use or try to use the FibroScan® ? *
ec
ho
se
ns
, t
he
ec
ho
se
ns
lo
go
, F
ibr
os
ca
n a
nd
th
e F
ibr
os
ca
n l
og
o a
re
re
gis
te
re
d t
ra
de
ma
rk
s o
F e
ch
os
en
s c
om
Pa
ny
© 2
00
7,
ec
ho
se
ns
, P
ar
is,
75
01
3 -
Ps
20
07
-07
en
HeadquarTerS - 42 rue monge - Fr-75005 pariScapiTaL aSSeTS : 162 603.00€ - vaT: Fr63 438 209 157
CANADA Kns Inc.
CHINA Furui
EGYPT Professional Medica
ENGLAND Artemis
HoNGKoNG Chong Lap
ITALY Axsan
JAPAN Intermedical Co. Ltd
KorEA Acme Medical Inc.
MArroCo Eramedic
roMANIA Temco
rUSSIA Delrus
SINGAPorE Transmedic
TAIWAN Medigiant
USA Sandhill Scientific
VIETNAM Khan Thien Trading Cie Ltd
List of our Distributors arounD the worLD
153 avenue d’iTaLie Fr-75013 pariS
T. + 33 1 44 82 78 50 F. + 33 1 44 82 78 60
c/ rodríguez San pedro 42 1°ceS-28015 madrid
T. +34 91 544 7325F. +34 91 544 7302
poppenBüTTeLer STraSSe 170de-22851 norderSTedT
T. +49 (0) 40 50 79 12 00F. +49 (0) 40 50 79 11 44
w w w . e C H o s e n s . C o m
